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A never-smoking 26-year-old woman presented at an outpa-tient clinic in February 2011 with cough, back pain, and 
weight loss. A computed tomography (CT) scan demonstrated 
a mass in the left lung, multiple bone, liver, and adrenal gland 
metastases. A liver biopsy revealed an adenocarcinoma origi-
nating from the lung (thyroid transcription factor-1 positive, 
EGFR and K-RAS wild type).
She was treated with cisplatin and pemetrexed, with 
stable disease after two cycles. Treatment continued with two 
cycles carboplatin and paclitaxel with again stable disease.
In the period from March till June she was radiated two 
times for symptomatic bone metastases. Next, she received 
erlotinib for 2 months, until progression occurred with a new 
metastasis in her right eye. In September, 1 month later, she 
gradually developed a paresis in both legs because of verte-
bral metastases that was treated with a single fraction of 8 Gy 
radiation.
In October 2011, the tumor was tested positive for 
echinoderm microtubule-associated protein-like 4-anaplastic 
lymphoma kinase translocation by fluorescence in situ hybrid-
ization. Crizotinib 250 mg twice daily was started. After 3 
days of treatment, she deteriorated and developed respiratory 
failure because of a right-sided pneumonia and pulmonary 
embolism on top of her massive tumor deposition throughout 
her body. She was transferred to the intensive care unit for 
noninvasive ventilation, antibiotics, and low-molecular hepa-
rin, in addition to crizotinib. Two days later, she reported sight 
in her previously blind right eye. Within a week, she was dis-
charged to our regular ward and home in the next week.
After 6 weeks, she returned to our outpatient clinic in a 
good condition. Her preexisting paresis remained stable. CT 
showed a partial response (55% tumor decrease, Response 
Evaluation Criteria in Solid Tumors 1.1, Fig. 1B). At 12 and 
18 weeks, further clinical improvement was observed and 
with positron emission tomography/CT imaging a near-com-
plete response (>90% tumor decrease) was noticed (Fig. 1C). 
At 6 months fluorodeoxyglucose uptake increased slightly in 
a few liver metastases, with a continuing partial response on 
CT (Fig. 1D). The patient is still receiving crizotinib at 47 
weeks.
DISCUSSION
In different cancer types genetic aberrations are found 
driving cells into a malignant phenotype and provide prolif-
eration advantages. In non–small-cell lung cancer (NSCLC) a 
subgroup of patients (2%–7%) with an ALK rearrangement has 
been identified.1,2 Specific inhibitors targeting this disrupted 
pathway have been studied.1,2 At present, the best studied 
drug is crizotinib, which shows promising results in NSCLC 
patients with fluorescence in situ hybridization–proven ALK 
rearrangements.2,3 The 2-year overall survival reached 54% 
(95% confidence interval, 40–66) with crizotinib, whereas the 
2-year survival for crizotinib-naive ALK-positive controls was 
36% (95% confidence interval, 19–54).3 The 57% response 
rate to crizotinib in this group and 84% disease control rate at 
8 weeks are major improvements compared with those with 
traditional chemotherapeutics.
Within 5 days of crizotinib treatment, vision started to 
recover from an ocular metastasis. This rapid tumor response 
is in line with a previous report.4
Our case highlights the potential of crizotinib treatment 
in patients with stage IV NSCLC, who harbor the EML4–ALK 
fusion gene, even with organ failure because of comorbidities 
in addition to a preexisting extensively metastasized disease.
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FIGURE 1.  Fluorodeoxyglucose 
positron emission tomography/
computed tomography scan show-
ing FDG uptake reflecting disease 
activity. A, Baseline (October 28, 
2011). B, Partial tumor response at 6 
weeks (December 8, 2011). C, Partial 
tumor response at 12 weeks (January 
17, 2012). D, Recurrent FDG uptake 
in the liver at 6 months (April 12, 
2012). FDG, fluorodeoxyglucose.
